45.18

0.85% 0.37

Exelixis Inc (EXEL)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché EXEL Giù? Forum Previsione

Precedente Chiudi:

$44.81

Aprire:

$44.64

Volume 24 ore:

610.01K

Relative Volume:

0.19

Capitalizzazione di mercato:

$12.32B

Reddito:

$2.17B

Utile/perdita netta:

$521.27M

Rapporto P/E:

25.53

EPS:

1.77

Flusso di cassa netto:

$633.79M

1 W Prestazione:

+0.04%

1M Prestazione:

+9.27%

6M Prestazione:

+24.83%

1 anno Prestazione:

+100.75%

Intervallo 1D:

$44.64

$45.52

Intervallo di 1 settimana:

$44.03

$45.90

Portata 52W:

$22.20

$49.62

Exelixis Inc Stock (EXEL) Company Profile

Nome

Exelixis Inc

Settore

Healthcare (1170)

Industria

Biotechnology (659)

Telefono

(650) 837-7000

Indirizzo

1851 HARBOR BAY PARKWAY, ALAMEDA, CA

Dipendente

1,147

Cinguettio

@exelixisinc

Prossima data di guadagno

2025-02-11

Ultimi documenti SEC

EXEL's Discussions on Twitter

Confronta EXEL con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
EXEL Exelixis Inc	45.18	12.02B	2.17B	521.27M	633.79M	1.77
VRTX Vertex Pharmaceuticals Inc	466.12	123.00B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	549.69	59.66B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	321.86	41.84B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	568.10	33.98B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	288.40	27.67B	3.81B	-644.79M	-669.77M	-6.24

Exelixis Inc Stock (EXEL) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-07-08	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2025-06-24	Aggiornamento	Stephens	Equal-Weight → Overweight
2025-02-24	Downgrade	Wells Fargo	Overweight → Equal Weight
2025-01-27	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2025-01-24	Downgrade	Oppenheimer	Outperform → Perform
2024-12-20	Downgrade	BMO Capital Markets	Outperform → Market Perform
2024-12-17	Downgrade	BofA Securities	Buy → Neutral
2024-10-16	Reiterato	RBC Capital Mkts	Outperform
2024-09-19	Iniziato	UBS	Neutral
2024-04-11	Downgrade	Barclays	Overweight → Equal Weight
2023-12-19	Iniziato	BTIG Research	Buy
2023-12-15	Iniziato	Citigroup	Buy
2023-09-26	Iniziato	H.C. Wainwright	Buy
2023-08-22	Reiterato	Oppenheimer	Outperform
2023-08-08	Iniziato	SVB Securities	Market Perform
2023-07-11	Ripresa	Morgan Stanley	Equal-Weight
2023-05-10	Ripresa	Piper Sandler	Overweight
2023-03-09	Iniziato	Wells Fargo	Overweight
2023-01-26	Iniziato	Credit Suisse	Outperform
2022-10-18	Iniziato	JMP Securities	Mkt Outperform
2022-06-24	Iniziato	BMO Capital Markets	Outperform
2021-11-19	Iniziato	Piper Sandler	Overweight
2021-11-03	Ripresa	Jefferies	Buy
2021-10-07	Iniziato	Jefferies	Buy
2021-08-06	Reiterato	H.C. Wainwright	Buy
2021-06-15	Iniziato	H.C. Wainwright	Buy
2021-05-18	Ripresa	Goldman	Sell
2021-03-31	Iniziato	Credit Suisse	Outperform
2021-03-12	Iniziato	Wolfe Research	Outperform
2020-03-04	Iniziato	Barclays	Overweight
2020-01-13	Iniziato	SunTrust	Buy
2019-11-13	Iniziato	BofA/Merrill	Buy
2019-03-18	Aggiornamento	Morgan Stanley	Underweight → Equal-Weight
2018-09-17	Iniziato	Goldman	Neutral
2018-09-10	Iniziato	Morgan Stanley	Underweight
2018-05-11	Reiterato	Needham	Buy
2017-10-17	Reiterato	Needham	Buy
2017-10-17	Reiterato	RBC Capital Mkts	Outperform
2017-10-16	Reiterato	SunTrust	Buy
2017-09-22	Downgrade	Leerink Partners	Outperform → Mkt Perform
2017-09-15	Iniziato	RBC Capital Mkts	Outperform
2017-09-12	Reiterato	Needham	Buy
2017-07-14	Iniziato	SunTrust	Buy
2017-03-31	Iniziato	Needham	Buy
2017-03-16	Iniziato	Oppenheimer	Perform
2017-02-28	Downgrade	Stifel	Buy → Hold
2016-11-03	Iniziato	Deutsche Bank	Buy
2016-10-10	Aggiornamento	Piper Jaffray	Neutral → Overweight
2016-09-15	Reiterato	Stifel	Buy

Mostra tutto

Exelixis Inc Borsa (EXEL) Ultime notizie

Jul 16, 2025

Exelixis Insiders Sell US$12m Of Stock, Possibly Signalling Caution - simplywall.st

Jul 16, 2025

Jul 15, 2025

Long Term Trading Analysis for (EXEL) - news.stocktradersdaily.com

Jul 15, 2025

Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance

Jul 15, 2025

Will Key Drugs Maintain Momentum for Novartis in Q2 Earnings? - The Globe and Mail

Jul 15, 2025

Truist Securities raises Exelixis stock price target to $56 on positive outlook - Investing.com Canada

Jul 15, 2025

Truist Lifts Price Target on Exelixis to $56 From $55, Keeps Buy Rating - MarketScreener

Jul 15, 2025

Jul 14, 2025

Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025 - BioSpace

Jul 14, 2025

Press Release: Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025 - 富途牛牛

Jul 14, 2025

Exelixis (EXEL) is an Incredible Growth Stock: 3 Reasons Why - sharewise.com

Jul 14, 2025

Jul 12, 2025

Analysts Offer Insights on Healthcare Companies: Medtronic (MDT) and Exelixis (EXEL) - The Globe and Mail

Jul 12, 2025

Jul 11, 2025

RBC Downgrades Exelixis to Sector Perform From Outperform, Lifts Price Target to $50 From $45 - MarketScreener

Jul 08, 2025

Exelixis (EXEL): Why Now is the Time to Act on Strong Clinical and Financial Catalysts - AInvest

Jul 08, 2025

Exelixis: I Was Wrong To Be Too Cautious (Rating Upgrade) - Seeking Alpha

Jul 08, 2025

Jul 07, 2025

Exelixis Surges 35.2% in Three Months: Buy or Sell the Stock? - The Globe and Mail

Jul 07, 2025

Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term - Yahoo Finance

Jul 07, 2025

Exelixis’s SWOT analysis: stock poised for growth amid pipeline progress - Investing.com

Jul 07, 2025

Jul 03, 2025

Zacks Industry Outlook Highlights Exelixis, Verona Pharma, Alkermes, Kiniska Pharmaceuticals and Immunocore - Yahoo Finance

Jul 03, 2025

Jul 02, 2025

Cancer index outperforms broader markets with 13% Q2 rebound - BioWorld MedTech

Jul 02, 2025

Jun 30, 2025